We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+12.89%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.25B
AUM Growth
+$226M
Cap. Flow
+$21M
Cap. Flow %
0.93%
Top 10 Hldgs %
73.64%
Holding
48
New
2
Increased
21
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$23.9M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$22.5M
3
ABMD
Abiomed Inc
ABMD
+$17.9M
4
INSM icon
Insmed
INSM
+$1.91M
5
UTHR icon
United Therapeutics
UTHR
+$1.8M

Top Sells

Rank Stock Value
1
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$27.4M
2
ALGN icon
Align Technology
ALGN
+$15M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$10.2M
4
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$4.95M
5
QLTI
QLT Inc
QLTI
+$1.24M

Sector Composition

Rank Sector Weight
1 Healthcare 69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLTQ
26
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$16.8M 0.74%
568,436
– –
RIGL icon
27
Rigel Pharmaceuticals
RIGL
$782M
$16.6M 0.74%
517,632
– –
ISRG icon
28
Intuitive Surgical
ISRG
$142B
$15.7M 0.7%
291,150
– –
ALIM
29
DELISTED
Alimera Sciences
ALIM
$13.9M 0.62%
200,920
– –
EXAS
30
DELISTED
Exact Sciences
EXAS
$11.7M 0.52%
392,676
– –
OREX
31
DELISTED
Orexigen Therapeutics, Inc.
OREX
$9.56M 0.43%
193,132
– –
TLPH icon
32
Talphera
TLPH
$72.7M
$9.06M 0.4%
106,787
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$4.55M 0.2%
9,029
+416
+5% +$191K
XOMA
34
DELISTED
Xoma
XOMA
$3.1M 0.14%
39,950
+225
+0.6% +$16.2K
OCGN icon
35
Ocugen
OCGN
$475M
$2.94M 0.13%
7,576
– –
VIRX
36
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.73M 0.12%
4,316
+1,443
+50% +$767K
BSTC
37
DELISTED
BioSpecifics Technologies Corp.
BSTC
$2.6M 0.12%
50,436
– –
PGEN icon
38
Precigen
PGEN
$2.45B
$2.3M 0.1%
47,524
-1,758
-4% -$74.1K
ALGN icon
39
Align Technology
ALGN
$12.4B
$1.74M 0.08%
27,757
-254,300
-90% -$15M
EPZM
40
DELISTED
Epizyme, Inc
EPZM
$1.47M 0.07%
+61,265
New +$1.18M
ARCT icon
41
Arcturus Therapeutics
ARCT
$216M
$1.02M 0.05%
22,370
+11,915
+114% +$546K
DRNA
42
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$986K 0.04%
+70,706
New +$1.3M
CYTK icon
43
Cytokinetics
CYTK
$10.5B
$831K 0.04%
123,686
– –
MNK
44
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$422K 0.02%
3,588
– –
SPHS
45
DELISTED
Sophiris Bio, Inc.
SPHS
$150K 0.01%
191,600
– –
EIGR
46
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-3,211
Closed -$27.4M
QLTI
47
DELISTED
QLT Inc
QLTI
– –
-315,906
Closed -$1.24M
SLXP
48
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-5,300
Closed -$916K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2015 Portfolio in Review

As of Q2 2015, Palo Alto Investors held 48 positions worth $2.25B, up 11% from $2.02B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors's Q2 2015 filing shows 2 new, 21 increased, 4 reduced and 3 closed positions. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 70,706 shares worth $986K. The largest sale was Eiger BioPharmaceuticals, Inc., an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier.

  • Palo Alto Investors's largest Q2 2015 buy was Dicerna Pharmaceuticals, Inc.: 70,706 shares worth $986K.
  • Palo Alto Investors added most to Clovis Oncology, Inc. in Q2 2015, an estimated $23.9M increase.
  • Palo Alto Investors's biggest Q2 2015 reduction was Align Technology, cutting an estimated $15M.
  • Palo Alto Investors fully exited Eiger BioPharmaceuticals, Inc. in Q2 2015, selling an estimated $27.4M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $2.25B portfolio in Q2 2015.
  • Palo Alto Investors opened 2 new positions and closed 3 in Q2 2015.
  • Palo Alto Investors's portfolio value rose 11% quarter-over-quarter to $2.25B.

Based on Palo Alto Investors's 13F filing for Q2 2015, filed 14 Aug 2015.